07:00 , Jun 9, 2014 |  BC Week In Review  |  Clinical News

3PO: Phase I started

Advanced Cancer Therapeutics began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV PFK-158, with a starting dose of 24 mg/m 2, in up to 48 patients with advanced solid tumors, including melanoma and...
07:00 , Mar 31, 2008 |  BC Week In Review  |  Company News

Advanced Cancer Therapeutics, University of Louisville deal

Advanced Cancer Therapeutics received an exclusive, worldwide license from the university to develop and commercialize 4-IPP and related compounds. The small molecule inhibitor of macrophage migration inhibitory factor (MIF) is in preclinical testing to...
07:00 , Mar 10, 2008 |  BC Week In Review  |  Company News

Advanced Cancer Therapeutics, University of Louisville deal

Advanced Cancer Therapeutics received an exclusive, worldwide license from the university to develop and market 3PO and related compounds to treat cancer. The inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 ( PFKFB3) is in preclinical testing to treat...